Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treating inflammation to combat non-alcoholic fatty liver disease
Leke Wiering, Frank Tacke
Journal of Endocrinology (2022) Vol. 256, Iss. 1
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Hepatic inflammatory responses in liver fibrosis
Linda Hammerich, Frank Tacke
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 633-646
Closed Access | Times Cited: 246
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Frank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 552-566
Closed Access | Times Cited: 135
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 764-783
Closed Access | Times Cited: 82
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Maurizio Parola, Massimo Pinzani
Molecular Aspects of Medicine (2023) Vol. 95, pp. 101231-101231
Open Access | Times Cited: 46
Major roles of kupffer cells and macrophages in NAFLD development
Soo-Jeung Park, Josefina Garcia Diaz, Eugene Um, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 29
Liver Injury and Regeneration: Current Understanding, New Approaches, and Future Perspectives
Shainan Hora, Torsten Wüestefeld
Cells (2023) Vol. 12, Iss. 17, pp. 2129-2129
Open Access | Times Cited: 25
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B. Patel
World Journal of Gastroenterology (2023) Vol. 29, Iss. 32, pp. 4831-4850
Open Access | Times Cited: 19
Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease
Jiong Wang, Yucheng Jiang, Leiming Jin, et al.
Nutrition and Diabetes (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)
Tobias Puengel, Frank Tacke
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 6, pp. 451-461
Closed Access | Times Cited: 11
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus
Monika Bhardwaj, Papiya Mitra Mazumder
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 4
Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives
Janitha M. Unagolla, Subarna Das, Riley Flanagan, et al.
International Journal of Pharmaceutics (2024) Vol. 660, pp. 124381-124381
Closed Access | Times Cited: 4
Advances in the Therapeutic Applications of Plant-Derived Exosomes in the Treatment of Inflammatory Diseases
Xiaofang Wei, Xiuyu Li, Yuejun Zhang, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1554-1554
Open Access | Times Cited: 11
C-C motif chemokine receptor 2 inhibition reduces liver fibrosis by restoring the immune cell landscape
Yangkun Guo, Chong Zhao, Wenting Dai, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 8, pp. 2572-2587
Open Access | Times Cited: 10
Effects of intermittent fasting regimens on glycemic, hepatic, anthropometric, and clinical markers in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis of randomized controlled trials
Saleh A. K. Saleh, Heitor O. Santos, Mihnea‐Alexandru Găman, et al.
Clinical Nutrition ESPEN (2023) Vol. 59, pp. 70-80
Closed Access | Times Cited: 10
Association of Systemic Immune-Inflammation Index with Non-Alcoholic Fatty Liver Disease: A Population-Based Cross-Sectional Study
Bi Zhao, Yuee Liu, Yi Yang, et al.
Risk Management and Healthcare Policy (2023) Vol. Volume 16, pp. 1581-1592
Open Access | Times Cited: 8
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, et al.
Medicina (2023) Vol. 59, Iss. 10, pp. 1789-1789
Open Access | Times Cited: 8
Association of Hematological Biomarkers of Inflammation with 10-Year Major Adverse Cardiovascular Events and All-Cause Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: The ARIC Study
Jia-Jie Wang, Zhichao Zheng, Ying Zhang
Journal of Inflammation Research (2024) Vol. Volume 17, pp. 4247-4256
Open Access | Times Cited: 2
Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative colitis
Beiying Deng, Yinghui Liu, Ying Chen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Prenatal Choline Supplement in a Maternal Obesity Model Modulates Offspring Hepatic Lipidomes
Hunter Korsmo, Isma’il Kadam, Aziza Reaz, et al.
Nutrients (2023) Vol. 15, Iss. 4, pp. 965-965
Open Access | Times Cited: 7
Efficacy and safety of carnitine supplementation on NAFLD: a systematic review and meta-analysis
Aiping Liu, Yitong Cai, Yuan Yuan, et al.
Systematic Reviews (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 6
Ambiguous Pathogenic Roles of Macrophages in Alcohol-Associated Liver Diseases
Yeni Ait Ahmed, Fouad Lafdil, Frank Tacke
Hepatic Medicine Evidence and Research (2023) Vol. Volume 15, pp. 113-127
Open Access | Times Cited: 6
New insights of DsbA-L in the pathogenesis of metabolic diseases
Siqi Li, Jinfa Wan, Zhenyu Peng, et al.
Molecular and Cellular Biochemistry (2024) Vol. 479, Iss. 12, pp. 3293-3303
Closed Access | Times Cited: 1
Remnant cholesterol is associated with the progression and regression of metabolic dysfunction-associated steatotic liver disease in Chinese adults
Wen Guo, Jing Lu, Xiaona Li, et al.
Journal of clinical lipidology (2024) Vol. 18, Iss. 4, pp. e509-e517
Closed Access | Times Cited: 1
Serum‐free light chains as a dependable biomarker for stratifying patients with metabolic dysfunction‐associated steatotic liver disease
Antonio Liguori, Francesca D’Ambrosio, Cecilia Napodano, et al.
Liver International (2024) Vol. 44, Iss. 10, pp. 2625-2638
Open Access | Times Cited: 1
Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
Merve Çebi, Yusuf Yılmaz
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top